{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T04:11:51Z","timestamp":1728965511127},"reference-count":63,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,14]]},"DOI":"10.7759\/cureus.71441","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T14:55:08Z","timestamp":1728917708000},"source":"Crossref","is-referenced-by-count":0,"title":["Role of Immunotherapy in Conjunction With the Surgical Treatment of Breast Cancer: Preoperative and Postoperative Applications"],"prefix":"10.7759","author":[{"given":"Nagma","family":"Sabu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hussein","family":"Attia Hussein Mahmoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Felipe","family":"Salazar Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nithin","family":"Naruboina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Esteban Rojas Prieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyanne","family":"Govender","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vegunta","family":"Ruthvik Phani Narayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhalala","family":"Priyank Batukbhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmin","family":"Ahmadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052856","article-title":"Nanomedicine-based delivery strategies for breast cancer treatment and management","volume":"23","author":"Tagde P","year":"2022","unstructured":"Tagde P, Najda A, Nagpal K, et al.. Nanomedicine-based delivery strategies for breast cancer treatment and management. Int J Mol Sci. 2022, 23:10.3390\/ijms23052856","journal-title":"Int J Mol Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/7549372","article-title":"Synthesis, structural characterization, and preclinical efficacy of a novel paclitaxel-loaded alginate nanoparticle for breast cancer treatment","volume":"2016","author":"Markeb AA","year":"2016","unstructured":"Markeb AA, El-Maali NA, Sayed DM, et al.. Synthesis, structural characterization, and preclinical efficacy of a novel paclitaxel-loaded alginate nanoparticle for breast cancer treatment. Int J Breast Cancer. 2016, 2016:7549372. 10.1155\/2016\/7549372","journal-title":"Int J Breast Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2018.07.011","article-title":"Emerging role and future directions of immunotherapy in advanced ovarian cancer","volume":"32","author":"Chodon T","year":"2018","unstructured":"Chodon T, Lugade AA, Battaglia S, Odunsi K. Emerging role and future directions of immunotherapy in advanced ovarian cancer. Hematol Oncol Clin North Am. 2018, 32:1025-39. 10.1016\/j.hoc.2018.07.011","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14071344","article-title":"Nanotechnology-based siRNA delivery systems to overcome tumor immune evasion in cancer immunotherapy","volume":"14","author":"Deng K","year":"2022","unstructured":"Deng K, Yang D, Zhou Y. Nanotechnology-based siRNA delivery systems to overcome tumor immune evasion in cancer immunotherapy. Pharmaceutics. 2022, 14:10.3390\/pharmaceutics14071344","journal-title":"Pharmaceutics"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/9585614","article-title":"Immunotherapies: exploiting the immune system for cancer treatment","volume":"2018","author":"Koury J","year":"2018","unstructured":"Koury J, Lucero M, Cato C, et al.. Immunotherapies: exploiting the immune system for cancer treatment. J Immunol Res. 2018, 2018:9585614. 10.1155\/2018\/9585614","journal-title":"J Immunol Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00315","article-title":"Immuno-oncology: emerging targets and combination therapies","volume":"8","author":"Marshall HT","year":"2018","unstructured":"Marshall HT, Djamgoz MB. Immuno-oncology: emerging targets and combination therapies. Front Oncol. 2018, 8:315. 10.3389\/fonc.2018.00315","journal-title":"Front Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/cells11162508","article-title":"PI3K\/AKT\/mTOR-targeted therapy for breast cancer","volume":"11","author":"Zhu K","year":"2022","unstructured":"Zhu K, Wu Y, He P, Fan Y, Zhong X, Zheng H, Luo T. PI3K\/AKT\/mTOR-targeted therapy for breast cancer. Cells. 2022, 11:2508. 10.3390\/cells11162508","journal-title":"Cells"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7150\/thno.69628","article-title":"Versatile carbon nanoplatforms for cancer treatment and diagnosis: strategies, applications and future perspectives","volume":"12","author":"Tang L","year":"2022","unstructured":"Tang L, Li J, Pan T, et al.. Versatile carbon nanoplatforms for cancer treatment and diagnosis: strategies, applications and future perspectives. Theranostics. 2022, 12:2290-321. 10.7150\/thno.69628","journal-title":"Theranostics"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2017.10.024","article-title":"Overcoming obstacles in the tumor microenvironment: recent advancements in nanoparticle delivery for cancer theranostics","volume":"156","author":"Overchuk M","year":"2018","unstructured":"Overchuk M, Zheng G. Overcoming obstacles in the tumor microenvironment: recent advancements in nanoparticle delivery for cancer theranostics. Biomaterials. 2018, 156:217-37. 10.1016\/j.biomaterials.2017.10.024","journal-title":"Biomaterials"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy518","article-title":"Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study","volume":"30","author":"Adams S","year":"2019","unstructured":"Adams S, Loi S, Toppmeyer D, et al.. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol. 2019, 30:405-11. 10.1093\/annonc\/mdy518","journal-title":"Ann Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-017-4537-5","article-title":"Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study","volume":"167","author":"Dirix LY","year":"2018","unstructured":"Dirix LY, Takacs I, Jerusalem G, et al.. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res Treat. 2018, 167:671-86. 10.1007\/s10549-017-4537-5","journal-title":"Breast Cancer Res Treat"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi L","year":"2020","unstructured":"Galluzzi L, Humeau J, Buqu\u00e9 A, Zitvogel L, Kroemer G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020, 17:725-41. 10.1038\/s41571-020-0413-z","journal-title":"Nat Rev Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/OP.22.00483","article-title":"Role of immunotherapy in breast cancer","volume":"19","author":"Jacob SL","year":"2023","unstructured":"Jacob SL, Huppert LA, Rugo HS. Role of immunotherapy in breast cancer. JCO Oncol Pract. 2023, 19:167-79. 10.1200\/OP.22.00483","journal-title":"JCO Oncol Pract"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2147\/BCTT.S432526","article-title":"Breast cancer: an overview of current therapeutic strategies, challenge, and perspectives","volume":"15","author":"Wang J","year":"2023","unstructured":"Wang J, Wu SG. Breast cancer: an overview of current therapeutic strategies, challenge, and perspectives. Breast Cancer (Dove Med Press). 2023, 15:721-30. 10.2147\/BCTT.S432526","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers8120106","article-title":"Advances in cancer immunotherapy in solid tumors","volume":"8","author":"Menon S","year":"2016","unstructured":"Menon S, Shin S, Dy G. Advances in cancer immunotherapy in solid tumors. Cancers (Basel). 2016, 8:10.3390\/cancers8120106","journal-title":"Cancers (Basel)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00325","article-title":"Combinations of immunotherapy and radiation in cancer therapy","volume":"4","author":"Vatner RE","year":"2014","unstructured":"Vatner RE, Cooper BT, Vanpouille-Box C, Demaria S, Formenti SC. Combinations of immunotherapy and radiation in cancer therapy. Front Oncol. 2014, 4:325. 10.3389\/fonc.2014.00325","journal-title":"Front Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol28050344","article-title":"Breast cancer surgery: new issues","volume":"28","author":"Magnoni F","year":"2021","unstructured":"Magnoni F, Alessandrini S, Alberti L, Polizzi A, Rotili A, Veronesi P, Corso G. Breast cancer surgery: new issues. Curr Oncol. 2021, 28:4053-66. 10.3390\/curroncol28050344","journal-title":"Curr Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-12133-8","article-title":"Does breast-conserving surgery with radiotherapy have a better survival than mastectomy? A meta-analysis of more than 1,500,000 patients","volume":"29","author":"De la Cruz Ku G","year":"2022","unstructured":"De la Cruz Ku G, Karamchandani M, Chambergo-Michilot D, et al.. Does breast-conserving surgery with radiotherapy have a better survival than mastectomy? A meta-analysis of more than 1,500,000 patients. Ann Surg Oncol. 2022, 29:6163-88. 10.1245\/s10434-022-12133-8","journal-title":"Ann Surg Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71221-5","article-title":"Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial","volume":"16","author":"Kunkler IH","year":"2015","unstructured":"Kunkler IH, Williams LJ, Jack WJL, Cameron DA, Dixon JM, PRIME II investigators. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol. 2015, 16:266-73. 10.1016\/S1470-2045(14)71221-5","journal-title":"Lancet Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12358","article-title":"Breast cancer: an up-to-date review and future perspectives","volume":"42","author":"Hong R","year":"2022","unstructured":"Hong R, Xu B. Breast cancer: an up-to-date review and future perspectives. Cancer Commun (Lond). 2022, 42:913-36. 10.1002\/cac2.12358","journal-title":"Cancer Commun (Lond)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx308","article-title":"De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017","volume":"28","author":"Curigliano G","year":"2017","unstructured":"Curigliano G, Burstein HJ, Winer EP, et al.. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017, 28:1700-12. 10.1093\/annonc\/mdx308","journal-title":"Ann Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102375","article-title":"Adjuvant and neoadjuvant breast cancer treatments: a systematic review of their effects on mortality","volume":"105","author":"Kerr AJ","year":"2022","unstructured":"Kerr AJ, Dodwell D, McGale P, et al.. Adjuvant and neoadjuvant breast cancer treatments: a systematic review of their effects on mortality. Cancer Treat Rev. 2022, 105:102375. 10.1016\/j.ctrv.2022.102375","journal-title":"Cancer Treat Rev"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby SC","year":"2013","unstructured":"Darby SC, Ewertz M, McGale P, et al.. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013, 368:987-98. 10.1056\/NEJMoa1209825","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11080808","article-title":"Breast cancer treatments: updates and new challenges","volume":"11","author":"Burguin A","year":"2021","unstructured":"Burguin A, Diorio C, Durocher F. Breast cancer treatments: updates and new challenges. J Pers Med. 2021, 11:10.3390\/jpm11080808","journal-title":"J Pers Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2022.02.003","article-title":"Global challenges in breast cancer detection and treatment","volume":"62","author":"Barrios CH","year":"2022","unstructured":"Barrios CH. Global challenges in breast cancer detection and treatment. Breast. 2022, 62:S3-6. 10.1016\/j.breast.2022.02.003","journal-title":"Breast"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15112912","article-title":"Chemo-immunotherapy: a new trend in cancer treatment","volume":"15","author":"Sordo-Bahamonde C","year":"2023","unstructured":"Sordo-Bahamonde C, Lorenzo-Herrero S, Gonzalez-Rodriguez AP, Mart\u00ednez-P\u00e9rez A, Rodrigo JP, Garc\u00eda-Pedrero JM, Gonzalez S. Chemo-immunotherapy: a new trend in cancer treatment. Cancers (Basel). 2023, 15:10.3390\/cancers15112912","journal-title":"Cancers (Basel)"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.109821","article-title":"Cancer immunotherapy: pros, cons and beyond","volume":"124","author":"Tan S","year":"2020","unstructured":"Tan S, Li D, Zhu X. Cancer immunotherapy: pros, cons and beyond. Biomed Pharmacother. 2020, 124:109821. 10.1016\/j.biopha.2020.109821","journal-title":"Biomed Pharmacother"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02965","article-title":"The intriguing history of cancer immunotherapy","volume":"10","author":"Dobosz P","year":"2019","unstructured":"Dobosz P, Dzieci\u0105tkowski T. The intriguing history of cancer immunotherapy. Front Immunol. 2019, 10:2965. 10.3389\/fimmu.2019.02965","journal-title":"Front Immunol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.919072","article-title":"Progress and prospect of immunotherapy for triple-negative breast cancer","volume":"12","author":"Luo C","year":"2022","unstructured":"Luo C, Wang P, He S, Zhu J, Shi Y, Wang J. Progress and prospect of immunotherapy for triple-negative breast cancer. Front Oncol. 2022, 12:919072. 10.3389\/fonc.2022.919072","journal-title":"Front Oncol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153801","article-title":"Systemic therapy for metastatic triple negative breast cancer: current treatments and future directions","volume":"15","author":"Morrison L","year":"2023","unstructured":"Morrison L, Okines A. Systemic therapy for metastatic triple negative breast cancer: current treatments and future directions. Cancers (Basel). 2023, 15:10.3390\/cancers15153801","journal-title":"Cancers (Basel)"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10050816","article-title":"Harnessing the immune system with cancer vaccines: from prevention to therapeutics","volume":"10","author":"Le I","year":"2022","unstructured":"Le I, Dhandayuthapani S, Chacon J, Eiring AM, Gadad SS. Harnessing the immune system with cancer vaccines: from prevention to therapeutics. Vaccines (Basel). 2022, 10:10.3390\/vaccines10050816","journal-title":"Vaccines (Basel)"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid P","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, et al.. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020, 382:810-21. 10.1056\/NEJMoa1910549","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2015.06.004","article-title":"Engineering CAR-T cells: design concepts","volume":"36","author":"Srivastava S","year":"2015","unstructured":"Srivastava S, Riddell SR. Engineering CAR-T cells: design concepts. Trends Immunol. 2015, 36:494-502. 10.1016\/j.it.2015.06.004","journal-title":"Trends Immunol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1002\/cai2.10","article-title":"Expert consensus on the clinical application of PI3K\/AKT\/mTOR inhibitors in the treatment of advanced breast cancer","volume":"1","year":"2022","unstructured":"Expert consensus on the clinical application of PI3K\/AKT\/mTOR inhibitors in the treatment of advanced breast cancer. Cancer Innov. 2022, 1.25-54. 10.1002\/cai2.10","journal-title":"Cancer Innov"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5825401","article-title":"Cancer vaccines: toward the next breakthrough in cancer immunotherapy","volume":"2020","author":"Igarashi Y","year":"2020","unstructured":"Igarashi Y, Sasada T. Cancer vaccines: toward the next breakthrough in cancer immunotherapy. J Immunol Res. 2020, 2020:5825401. 10.1155\/2020\/5825401","journal-title":"J Immunol Res"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-021-00796-4","article-title":"An overview of PARP inhibitors for the treatment of breast cancer","volume":"16","author":"Cortesi L","year":"2021","unstructured":"Cortesi L, Rugo HS, Jackisch C. An overview of PARP inhibitors for the treatment of breast cancer. Target Oncol. 2021, 16:255-82. 10.1007\/s11523-021-00796-4","journal-title":"Target Oncol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpet.2018.02.006","article-title":"Overview of breast cancer therapy","volume":"13","author":"Moo TA","year":"2018","unstructured":"Moo TA, Sanford R, Dang C, Morrow M. Overview of breast cancer therapy. PET Clin. 2018, 13:339-54. 10.1016\/j.cpet.2018.02.006","journal-title":"PET Clin"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.2174\/1570163812666150602144310","article-title":"Targeted cancer therapy: the next generation of cancer treatment","volume":"12","author":"T. Baudino","year":"2015","unstructured":"T. Baudino. Targeted cancer therapy: the next generation of cancer treatment. Curr Drug Discov Technol. 2015, 12:3-20. 10.2174\/1570163812666150602144310","journal-title":"Curr Drug Discov Technol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01805-y","article-title":"Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer","volume":"22","author":"Ye F","year":"2023","unstructured":"Ye F, Dewanjee S, Li Y, et al.. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer. 2023, 22:105. 10.1186\/s12943-023-01805-y","journal-title":"Mol Cancer"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0398-7","article-title":"Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity","volume":"6","author":"Bakos O","year":"2018","unstructured":"Bakos O, Lawson C, Rouleau S, Tai LH. Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity. J Immunother Cancer. 2018, 6:86. 10.1186\/s40425-018-0398-7","journal-title":"J Immunother Cancer"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24867","article-title":"A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer","volume":"9","author":"Santa-Maria CA","year":"2018","unstructured":"Santa-Maria CA, Kato T, Park JH, et al.. A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer. Oncotarget. 2018, 9:18985-96. 10.18632\/oncotarget.24867","journal-title":"Oncotarget"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00508-3","article-title":"Immunotherapy in breast cancer: an overview of current strategies and perspectives","volume":"9","author":"Debien V","year":"2023","unstructured":"Debien V, De Caluw\u00e9 A, Wang X, Piccart-Gebhart M, Tuohy VK, Romano E, Buisseret L. Immunotherapy in breast cancer: an overview of current strategies and perspectives. NPJ Breast Cancer. 2023, 9:7. 10.1038\/s41523-023-00508-3","journal-title":"NPJ Breast Cancer"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour L","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A, et al.. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017, 18:e143-52. 10.1016\/S1470-2045(17)30074-8","journal-title":"Lancet Oncol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.506","article-title":"Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline\/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC)","volume":"39","author":"Loibl S","year":"2021","unstructured":"Loibl S, Schneeweiss A, Huober J, et al.. Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline\/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC). J Clin Oncol. 2021, 39:506. 10.1200\/JCO.2021.39.15_suppl.506","journal-title":"J Clin Oncol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-021-06480-5","article-title":"Immunotherapy toxicity: identification and management","volume":"192","author":"Gumusay O","year":"2022","unstructured":"Gumusay O, Callan J, Rugo HS. Immunotherapy toxicity: identification and management. Breast Cancer Res Treat. 2022, 192:1-17. 10.1007\/s10549-021-06480-5","journal-title":"Breast Cancer Res Treat"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2021.11.043","article-title":"Localized delivery of immunotherapy via implantable scaffolds for breast cancer treatment","volume":"341","author":"Hope A","year":"2022","unstructured":"Hope A, Wade SJ, Aghmesheh M, Vine KL. Localized delivery of immunotherapy via implantable scaffolds for breast cancer treatment. J Control Release. 2022, 341:399-413. 10.1016\/j.jconrel.2021.11.043","journal-title":"J Control Release"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-023-00224-9","article-title":"Immune checkpoint inhibitors in breast cancer: a narrative review","volume":"11","author":"Nunes Filho P","year":"2023","unstructured":"Nunes Filho P, Albuquerque C, Pilon Capella M, Debiasi M. Immune checkpoint inhibitors in breast cancer: a narrative review. Oncol Ther. 2023, 11:171-83. 10.1007\/s40487-023-00224-9","journal-title":"Oncol Ther"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.2635","article-title":"Late immune-related adverse events with immune checkpoint inhibitors","volume":"39","author":"Andrew Ip","unstructured":"Andrew Ip, Shuo Wang, Divya Cheruku, et al.. Late immune-related adverse events with immune checkpoint inhibitors. J Clin Oncol. 39:2635. 10.1200\/JCO.2021.39.15_suppl.2635","journal-title":"J Clin Oncol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-024-15359-w","article-title":"Impact of neoadjuvant chemoimmunotherapy on surgical outcomes and time to radiation in triple-negative breast cancer","volume":"31","author":"Myers SP","year":"2024","unstructured":"Myers SP, Sevilimedu V, Jones VM, et al.. Impact of neoadjuvant chemoimmunotherapy on surgical outcomes and time to radiation in triple-negative breast cancer. Ann Surg Oncol. 2024, 31:5180-8. 10.1245\/s10434-024-15359-w","journal-title":"Ann Surg Oncol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0275321","article-title":"The adverse effects of trastuzumab-containing regimes as a therapy in breast cancer: a piggy-back systematic review and meta-analysis","volume":"17","author":"Jackson C","year":"2022","unstructured":"Jackson C, Finikarides L, Freeman AL. The adverse effects of trastuzumab-containing regimes as a therapy in breast cancer: a piggy-back systematic review and meta-analysis. PLoS One. 2022, 17:e0275321. 10.1371\/journal.pone.0275321","journal-title":"PLoS One"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.2217\/fon.15.222","article-title":"Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis","volume":"12","author":"Abdel-Rahman O","year":"2016","unstructured":"Abdel-Rahman O, ElHalawani H, Fouad M. Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis. Future Oncol. 2016, 12:413-25. 10.2217\/fon.15.222","journal-title":"Future Oncol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.7150\/jca.85433","article-title":"PD-1\/PD-L1 inhibitor - related adverse events and their management in breast cancer","volume":"15","author":"Lei C","year":"2024","unstructured":"Lei C, Kong X, Li Y, et al.. PD-1\/PD-L1 inhibitor - related adverse events and their management in breast cancer. J Cancer. 2024, 15:2770-87. 10.7150\/jca.85433","journal-title":"J Cancer"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.3390\/medsci10020027","article-title":"New insights on the toxicity on heart and vessels of breast cancer therapies","volume":"10","author":"Lanza O","year":"2022","unstructured":"Lanza O, Ferrera A, Reale S, et al.. New insights on the toxicity on heart and vessels of breast cancer therapies. Med Sci (Basel). 2022, 10:10.3390\/medsci10020027","journal-title":"Med Sci (Basel)"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid P","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, et al.. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018, 379:2108-21. 10.1056\/NEJMoa1809615","journal-title":"N Engl J Med"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8931","article-title":"Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study","volume":"34","author":"Nanda R","year":"2016","unstructured":"Nanda R, Chow LQ, Dees EC, et al.. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol. 2016, 34:2460-7. 10.1200\/JCO.2015.64.8931","journal-title":"J Clin Oncol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot JM","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, et al.. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016, 54:139-48. 10.1016\/j.ejca.2015.11.016","journal-title":"Eur J Cancer"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2020.5135","article-title":"Triple\u2011negative breast cancer therapy: current and future perspectives (Review)","volume":"57","author":"Won KA","year":"2020","unstructured":"Won KA, Spruck C. Triple\u2011negative breast cancer therapy: current and future perspectives (Review). Int J Oncol. 2020, 57:1245-61. 10.3892\/ijo.2020.5135","journal-title":"Int J Oncol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15071796","article-title":"Triple negative breast cancer treatment options and limitations: future outlook","volume":"15","author":"Obidiro O","year":"2023","unstructured":"Obidiro O, Battogtokh G, Akala EO. Triple negative breast cancer treatment options and limitations: future outlook. Pharmaceutics. 2023, 15:10.3390\/pharmaceutics15071796","journal-title":"Pharmaceutics"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092136","article-title":"Immunotherapy for HER2-positive breast cancer: clinical evidence and future perspectives","volume":"14","author":"Agostinetto E","year":"2022","unstructured":"Agostinetto E, Montemurro F, Puglisi F, et al.. Immunotherapy for HER2-positive breast cancer: clinical evidence and future perspectives. Cancers (Basel). 2022, 14:2136. 10.3390\/cancers14092136","journal-title":"Cancers (Basel)"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-023-01069-0","article-title":"Immunotherapy for metastatic triple negative breast cancer: current paradigm and future approaches","volume":"24","author":"Geurts V","year":"2023","unstructured":"Geurts V, Kok M. Immunotherapy for metastatic triple negative breast cancer: current paradigm and future approaches. Curr Treat Options Oncol. 2023, 24:628-43. 10.1007\/s11864-023-01069-0","journal-title":"Curr Treat Options Oncol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107886","article-title":"Breast cancer immunotherapy: current and novel approaches","volume":"98","author":"Barzaman K","year":"2021","unstructured":"Barzaman K, Moradi-Kalbolandi S, Hosseinzadeh A, Kazemi MH, Khorramdelazad H, Safari E, Farahmand L. Breast cancer immunotherapy: current and novel approaches. Int Immunopharmacol. 2021, 98:107886. 10.1016\/j.intimp.2021.107886","journal-title":"Int Immunopharmacol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1385571","article-title":"CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies","volume":"15","author":"Niu Z","year":"2024","unstructured":"Niu Z, Wu J, Zhao Q, Zhang J, Zhang P, Yang Y. CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies. Front Immunol. 2024, 15:1385571. 10.3389\/fimmu.2024.1385571","journal-title":"Front Immunol"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0798-2","article-title":"Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives","volume":"12","author":"Krasniqi E","year":"2019","unstructured":"Krasniqi E, Barchiesi G, Pizzuti L, et al.. Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives. J Hematol Oncol. 2019, 12:111. 10.1186\/s13045-019-0798-2","journal-title":"J Hematol Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/301555-role-of-immunotherapy-in-conjunction-with-the-surgical-treatment-of-breast-cancer-preoperative-and-postoperative-applications","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T14:55:10Z","timestamp":1728917710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/301555-role-of-immunotherapy-in-conjunction-with-the-surgical-treatment-of-breast-cancer-preoperative-and-postoperative-applications"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":63,"URL":"https:\/\/doi.org\/10.7759\/cureus.71441","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,14]]}}}